EUVIMEDEUVIMED entdecken
Crossref

Minimally Invasive Thymectomy for Myasthenia Gravis: Feasibility and Functional Outcomes

Nicolas Mwesigwa iD, Abdulla Al-Shamari, Samsul Islam, Tasnim Chowdhury, Ibrahim Ibrahim, Pablo Garcia-Reitboeck, Jeremy Smelt

The Thoracic and Cardiovascular Surgeon · 07.10.2026

DOI: 10.1055/a-2969-6473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 07.10.2026. Verfasst von Nicolas Mwesigwa und 6 weiteren Autor:innen. Beteiligte Einrichtung: St George's Hospital, Department of Thoracic Surgery, United Kingdom, London. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thymectomy is established for myasthenia gravis (MG), but evidence from non-specialist general thoracic surgery units is limited. This study evaluates the feasibility and outcomes of thymectomy following an institutional transition from sternotomy to minimally invasive surgery, and assesses MG Composite and MG-ADL scores as longitudinal outcome measures. A single-center retrospective cohort study of 58 consecutive patients who underwent MG thymectomy between 2018 and 2026. The primary outcome was favorable clinical status (complete stable remission or improvement) at 1 year. Secondary outcomes included complications, length of stay, medication reduction, and changes in MG Composite score. Between-group comparisons across surgical approaches are descriptive and exploratory only. Surgical approaches were robotic-assisted thoracic surgery (RATS; n = 29; 50.0%), video-assisted thoracoscopic surgery (VATS; n = 22; 37.9%), and sternotomy (n = 7; 12.1%). Perioperative mortality was zero. Overall complication rate was 10.3%. A favorable outcome was achieved in 68.9% (95% CI: 57.3–81.9%). Sternotomy was associated with longer hospital stay (median 7 vs. 2–3 days; p = 0.02). Prednisolone and pyridostigmine were reduced or discontinued in 72.1 and 55.3% of preoperative users, respectively (both p < 0.001). MG Composite and MG-ADL scores improved progressively from 3 months onward. Thymectomy can be safely and effectively performed in a general thoracic surgery unit with appropriate specialist input, achieving outcomes comparable to regional referral centers. Apparently, transition to minimally invasive surgery did not compromise safety or efficacy while significantly reducing hospital stay. Future studies should collect MG Composite and MG-ADL scores prospectively as standardized outcome measures.

Autor:innen und Institutionen

  • St George's Hospital, Department of Thoracic Surgery, United Kingdom, London.
  • St George's University Hospitals NHS Foundation Trust, Department of Thoracic Surgery, United Kingdom, London.
  • St George's NHS Foundation Trust, Department of Thoracic Surgery, United Kingdom, London.
  • St George's NHS Foundation Trust, Department of Cardiothoracic Anaesthesia, United Kingdom, London.
  • St George's NHS Foundation Trust, Department of Neurology, United Kingdom, London.

ORCID-Profile: Nicolas Mwesigwa

Zitieren

APA

Mwesigwa, N., Al-Shamari, A., Islam, S., Chowdhury, T., Ibrahim, I., Garcia-Reitboeck, P., & Smelt, J. (2026). Minimally Invasive Thymectomy for Myasthenia Gravis: Feasibility and Functional Outcomes. The Thoracic and Cardiovascular Surgeon. https://doi.org/10.1055/a-2969-6473

Vancouver

Mwesigwa N, Al-Shamari A, Islam S, Chowdhury T, Ibrahim I, Garcia-Reitboeck P, et al. Minimally Invasive Thymectomy for Myasthenia Gravis: Feasibility and Functional Outcomes. The Thoracic and Cardiovascular Surgeon. 2026. doi:10.1055/a-2969-6473

BibTeX
@article{Mwesigwa2026,
  author = {Mwesigwa, Nicolas and Al-Shamari, Abdulla and Islam, Samsul and Chowdhury, Tasnim and Ibrahim, Ibrahim and Garcia-Reitboeck, Pablo and Smelt, Jeremy},
  title = {Minimally Invasive Thymectomy for Myasthenia Gravis: Feasibility and Functional Outcomes},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2026},
  doi = {10.1055/a-2969-6473}
}
Kostenlos starten →